The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Cancer-Associated Thrombosis: Management

Anticoagulation strategy for venous thromboembolism in cancer

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Cancer-Associated Thrombosis: Management?

Cancer-associated thrombosis (CAT) is one of the leading non-cancer causes of death in patients with malignancy. Hypercoagulability arises from tumor production of tissue factor and other procoagulants, immobility, surgery, central venous catheters, and chemotherapy effects. Pancreatic, gastric, brain, lung, and ovarian cancers carry particularly high risk.

For acute venous thromboembolism, current ASCO and ASH guidelines recommend a direct oral anticoagulant (apixaban, rivaroxaban, or edoxaban) as first-line for most patients. Apixaban tends to be preferred in patients with luminal gastrointestinal cancer due to lower bleeding risk than edoxaban or rivaroxaban. Low molecular weight heparin remains a strong option, especially with active gastrointestinal mucosal lesions, severe thrombocytopenia, or drug interaction concerns.

Treatment duration is at least six months and continues as long as the cancer is active. Recurrent thrombosis on therapeutic anticoagulation is managed by switching agents or escalating LMWH dose by twenty-five percent. Primary prophylaxis with LMWH or apixaban is considered for ambulatory patients receiving high-risk chemotherapy with a Khorana score of two or higher.

Symptoms

Calf or thigh swelling and pain
Sudden chest pain and shortness of breath
Hemoptysis or pleuritic chest pain
Headache and neurologic deficit (cerebral vein thrombosis)
Abdominal pain (splanchnic vein thrombosis)
Catheter-associated upper limb DVT

Risk Factors

Pancreatic, gastric, brain, lung, ovarian cancer
Active chemotherapy or immunotherapy
Indwelling central venous catheter
Recent surgery or hospitalization
Prior thromboembolism, obesity, immobility

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Sudden leg swelling, especially in cancer patient
  • Sudden chest pain or shortness of breath
  • New severe headache or focal neurologic symptom
  • Severe abdominal pain in pancreatic or hematologic cancer

Treatment Methods

01
Apixaban, rivaroxaban, or edoxaban as first-line for most patients
02
Apixaban or LMWH for luminal gastrointestinal cancer
03
LMWH for severe thrombocytopenia or drug interaction concern
04
Treatment for at least six months and while cancer is active
05
Khorana score-based primary prophylaxis with apixaban or LMWH
06
Catheter retention if functioning unless septic or refractory thrombosis
07
Bleeding risk assessment at every visit

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.